ZLSCF (ZYUS Life Sciences) E10: $ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLSCF ZYUS Life Sciences Corp ZLSCF
21 GF Score
Price $0.60
GF Value $0.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences E10?

ZYUS Life Sciences ZLSCF -6.89% 21 E10 is $ as of Jun. 2026. GuruFocus rates ZLSCF with a GF Score™ of 21/100 and a GF Value™ of $0.55 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ZYUS Life Sciences's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.027. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $ for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-09-21), ZYUS Life Sciences's current stock price is $0.60. ZYUS Life Sciences's E10 for the quarter that ended in Jun. 2026 was $. ZYUS Life Sciences's Shiller PE Ratio of today is .


ZYUS Life Sciences  (OTCPK:ZLSCF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ZYUS Life Sciences E10 Related Terms


ZYUS Life Sciences E10 Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences E10 Chart

ZYUS Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ZYUS Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ZLSCF vs SKYI, CBDY, NPHC: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Shiller PE Ratio falls into.


ZLSCF
21GF Score
ZYUS Life Sciences Corp ZLSCF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ZYUS Life Sciences's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.0273/133.5265*133.5265
=-0.027

Current CPI (Jun. 2026) = 133.5265.

ZYUS Life Sciences Quarterly Data

per share eps CPI Adj_EPS
201609 0.031 101.765 0.040
201612 0.011 101.449 0.015
201703 0.008 102.634 0.010
201706 0.022 103.029 0.029
201709 0.016 103.345 0.021
201712 0.016 103.345 0.020
201803 -0.018 105.004 -0.023
201806 -0.016 105.557 -0.020
201809 -0.021 105.636 -0.027
201812 -0.047 105.399 -0.060
201903 0.044 106.979 0.055
201906 -0.010 107.690 -0.013
201909 0.006 107.611 0.008
201912 0.001 107.769 0.001
202003 -0.133 107.927 -0.165
202006 0.012 108.401 0.015
202009 -0.003 108.164 -0.003
202012 0.016 108.559 0.020
202103 0.037 110.298 0.044
202106 0.019 111.720 0.023
202109 -0.004 112.905 -0.005
202112 0.004 113.774 0.005
202203 0.016 117.646 0.019
202206 -0.119 120.806 -0.131
202209 -0.146 120.648 -0.161
202212 -0.115 120.964 -0.127
202303 -0.093 122.702 -0.101
202306 -0.150 124.203 -0.161
202309 -0.045 125.230 -0.048
202312 -0.254 125.072 -0.271
202403 -0.035 126.258 -0.037
202406 -0.050 127.522 -0.052
202409 -0.040 127.285 -0.042
202412 -0.209 127.364 -0.219
202503 -0.037 129.181 -0.038
202506 -0.042 129.892 -0.043
202509 -0.034 130.287 -0.035
202512 -0.087 130.366 -0.089
202603 -0.028 132.262 -0.028
202606 -0.027 133.527 -0.027

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $ mean?
ZYUS Life Sciences (ZLSCF) has a E10 of $ as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on ZYUS Life Sciences and its competitors.
Is ZYUS Life Sciences' E10 too high?
ZYUS Life Sciences' current E10 is $. Overall, ZYUS Life Sciences has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' E10 compare to SKYI and CBDY?
ZYUS Life Sciences' E10 of $ can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current E10 is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Fairly Valued. The stock's GF Value™ is $0.55, compared to a current price of $0.60 — trading 9.1% above its estimated fair value. The current E10 is $. ZYUS Life Sciences' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current E10 is $ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?

Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued. The current stock price of $0.60 is trading 9.1% above its estimated GF Value™ of $0.55. GuruFocus considers ZYUS Life Sciences to be Fairly Valued.

Key valuation signals for ZLSCF:

  • E10: $
  • GF Value™: $0.55 vs. price of $0.60 (9.1% above fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score

Get the complete analysis for ZLSCF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.55
GF Value